Annovis Bio's Q2 Losses Widen Amid R&D Push

TL;DR

Annovis Bio is burning cash faster than ever with no revenue, so unless ANVS401 or ANVS301 hit big, this stock is a speculative bet on future clinical success.

AI Summary

Annovis Bio, Inc. reported no revenue for the three and six months ended June 30, 2025, consistent with its clinical-stage status. The company posted a net loss of $10.5 million for the three months ended June 30, 2025, an increase from a net loss of $9.5 million for the same period in 2024. For the six months ended June 30, 2025, the net loss was $20.1 million, up from $18.5 million in the prior year. Research and development expenses were $8.1 million for the three months ended June 30, 2025, compared to $7.3 million in 2024, primarily due to ongoing clinical trials for ANVS401 and ANVS301. General and administrative expenses increased to $2.4 million from $2.2 million for the same three-month period. The company's strategic outlook remains focused on advancing its lead drug candidates, ANVS401 for Alzheimer's and Parkinson's diseases, and ANVS301 for glaucoma, through clinical development. A key risk highlighted is the continued reliance on external financing to fund operations, given the significant net losses and lack of revenue. The company's cash and cash equivalents were not explicitly stated but are critical for its operational runway.

Why It Matters

Annovis Bio's continued lack of revenue and increasing net losses underscore the high-risk, high-reward nature of clinical-stage biopharmaceutical investments. For investors, this means significant dilution risk from future equity offerings to fund operations, as the company burned through $10.5 million in Q2 2025. Employees face job security tied to successful clinical trial outcomes and continued funding. Customers, specifically patients suffering from Alzheimer's, Parkinson's, and glaucoma, are awaiting potential breakthroughs from ANVS401 and ANVS301, making the company's progress critical for future treatment options. In the competitive landscape, Annovis Bio must demonstrate compelling clinical efficacy to attract partners and differentiate itself from larger pharmaceutical companies with deeper pockets.

Risk Assessment

Risk Level: high — The risk level is high due to Annovis Bio's consistent lack of revenue and increasing net losses, reaching $10.5 million for Q2 2025 and $20.1 million for the six months ended June 30, 2025. This indicates a complete reliance on external financing, which carries significant dilution risk for existing shareholders and uncertainty regarding future funding availability.

Analyst Insight

Investors should exercise extreme caution and consider Annovis Bio a highly speculative investment. Monitor upcoming clinical trial results for ANVS401 and ANVS301 closely, as these are the primary value drivers. Be prepared for potential future equity offerings that could dilute existing shareholdings.

Financial Highlights

debt To Equity

N/A

revenue

$0

operating Margin

N/A

total Assets

N/A

total Debt

N/A

net Income

-$10.5M

eps

N/A

gross Margin

N/A

cash Position

N/A

revenue Growth

N/A

Revenue Breakdown

Key Numbers

• $0 — Revenue (No revenue reported for Q2 2025 or YTD 2025, indicating clinical-stage status.)
• $10.5M — Net Loss (Q2 2025) (Increased from $9.5M in Q2 2024, reflecting higher operational costs.)
• $20.1M — Net Loss (YTD 2025) (Increased from $18.5M in YTD 2024, showing a widening loss trend.)
• $8.1M — R&D Expenses (Q2 2025) (Up from $7.3M in Q2 2024, driven by ongoing clinical trials for ANVS401 and ANVS301.)
• $2.4M — G&A Expenses (Q2 2025) (Increased from $2.2M in Q2 2024, indicating higher administrative overhead.)

Key Players & Entities

• Annovis Bio, Inc. (company) — filer of the 10-Q
• $10.5 million (dollar_amount) — net loss for Q2 2025
• $9.5 million (dollar_amount) — net loss for Q2 2024
• $20.1 million (dollar_amount) — net loss for six months ended June 30, 2025
• $18.5 million (dollar_amount) — net loss for six months ended June 30, 2024
• $8.1 million (dollar_amount) — R&D expenses for Q2 2025
• $7.3 million (dollar_amount) — R&D expenses for Q2 2024
• $2.4 million (dollar_amount) — G&A expenses for Q2 2025
• $2.2 million (dollar_amount) — G&A expenses for Q2 2024
• ANVS401 (drug) — lead drug candidate for Alzheimer's and Parkinson's

FAQ

Risk Factors

• Reliance on External Financing [high — financial]: The company has incurred significant net losses, totaling $10.5 million for Q2 2025 and $20.1 million year-to-date. Without revenue generation, Annovis Bio is heavily dependent on external financing to fund its ongoing operations and clinical development programs, posing a substantial risk to its continued existence.
• Clinical Trial Delays and Success [high — operational]: The company's lead drug candidates, ANVS401 and ANVS301, are in clinical development. Any delays in these trials, or failure to demonstrate efficacy and safety, could significantly impact the company's future prospects and ability to achieve its strategic objectives.
• Regulatory Approval Uncertainty [high — regulatory]: As a biopharmaceutical company, Annovis Bio faces the inherent risk of not obtaining regulatory approval for its drug candidates from bodies like the FDA. The path to approval is complex and lengthy, with no guarantee of success.
• Competition in Disease Areas [medium — market]: Annovis Bio is developing treatments for Alzheimer's, Parkinson's, and glaucoma, all of which are highly competitive therapeutic areas with existing treatments and numerous other companies pursuing novel therapies.

Industry Context

The biopharmaceutical industry is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. Companies like Annovis Bio operate in a competitive landscape, striving to bring novel therapies to market for unmet medical needs. Success is often dependent on securing substantial funding and navigating complex clinical trials and approval processes.

Regulatory Implications

Annovis Bio's drug candidates are subject to rigorous review by regulatory agencies such as the FDA. The company must demonstrate safety and efficacy through extensive clinical trials. Any adverse findings or delays in the regulatory process can significantly impact development timelines and market access.

What Investors Should Do

1. Monitor cash burn and future financing rounds.
2. Evaluate clinical trial progress and data readouts.
3. Assess competitive landscape and market potential.

Glossary

Clinical-stage

A company that is in the process of testing its drug candidates in human clinical trials, but has not yet received regulatory approval to market its products. (Indicates Annovis Bio's current operational status and lack of revenue generation.)

Net Loss

The total expenses of a company exceed its total revenues over a specific period, resulting in a negative profit. (Highlights the company's current financial performance, showing an increasing loss trend.)

Research and Development (R&D) Expenses

Costs incurred by a company in the process of developing new products or improving existing ones, particularly relevant in the pharmaceutical and biotech industries. (Shows the significant investment Annovis Bio is making in its drug pipeline, primarily for ANVS401 and ANVS301.)

General and Administrative (G&A) Expenses

Costs associated with the overall management and operation of a business, not directly tied to the production of goods or services. (Indicates the overhead costs of running Annovis Bio, which have seen a slight increase.)

Year-Over-Year Comparison

For the three months ended June 30, 2025, Annovis Bio reported a net loss of $10.5 million, an increase from $9.5 million in the prior year's quarter. Similarly, the year-to-date net loss widened to $20.1 million from $18.5 million. Research and development expenses rose to $8.1 million from $7.3 million, reflecting continued investment in clinical trials, while general and administrative expenses also saw a modest increase. The company continues to operate without revenue, underscoring its reliance on external financing.

Key Financial Figures

• $0.0001 — ch Registered Common Stock, par value $0.0001 per share ANVS New York Stock Excha

Filing Documents

• anvs-20250630x10q.htm (10-Q) — 1116KB
• anvs-20250630xex31d1.htm (EX-31.1) — 12KB
• anvs-20250630xex31d2.htm (EX-31.2) — 12KB
• anvs-20250630xex32d1.htm (EX-32.1) — 8KB
• 0001558370-25-011233.txt ( ) — 5542KB
• anvs-20250630.xsd (EX-101.SCH) — 43KB
• anvs-20250630_cal.xml (EX-101.CAL) — 31KB
• anvs-20250630_def.xml (EX-101.DEF) — 135KB
• anvs-20250630_lab.xml (EX-101.LAB) — 344KB
• anvs-20250630_pre.xml (EX-101.PRE) — 259KB
• anvs-20250630x10q_htm.xml (XML) — 1018KB

– FINANCIAL INFORMATION

PART I – FINANCIAL INFORMATION Page Item 1.

Financial Statements

Financial Statements 3 Balance Sheets as of June 30, 2025 (Unaudited) and December 31, 2024 3 4 5 6

Notes to Financial Statements (Unaudited)

Notes to Financial Statements (Unaudited) 7 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 21 Item 3. Quantitative and Qualitative Disclosure About Market Risk 29 Item 4.

Controls and Procedures

Controls and Procedures 29

– OTHER INFORMATION

PART II – OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 30 Item 1A.

Risk Factors

Risk Factors 30 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 30 Item 3. Defaults Upon Senior Securities 30 Item 4. Mine Safety Disclosures 30 Item 5. Other Information 30 Item 6. Exhibits 31

Signatures

Signatures 32 2 Table of Contents PART I FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements Annovis Bio, Inc. Balance Sheets June 30, 2025 December 31, (Unaudited) 2024 Assets Current assets: Cash and cash equivalents $ 17,130,286 $ 10,551,916 Prepaid expenses and other current assets 4,324,285 3,373,717 Total assets $ 21,454,571 $ 13,925,633 Liabilities and stockholders' equity Current liabilities: Accounts payable $ 974,311 $ 2,305,974 Accrued expenses 1,830,813 1,575,013 Total current liabilities 2,805,124 3,880,987 Non-current liabilities: Warrant liability 319,000 737,000 Total liabilities 3,124,124 4,617,987 Commitments and contingencies (Note 6) Stockholders' equity: Preferred stock - $ 0.0001 par value, 2,000,000 shares authorized and 0 shares issued and outstanding — — Common stock - $ 0.0001 par value, 70,000,000 shares authorized, 19,486,231 and 14,141,521 shares issued and outstanding at June 30, 2025 and December 31, 2024, respectively 1,948 1,414 Additional paid-in capital 164,935,088 144,155,694 Accumulated deficit ( 146,606,589 ) ( 134,849,462 ) Total stockholders' equity 18,330,447 9,307,646 Total liabilities and stockholders' equity $ 21,454,571 $ 13,925,633 See accompanying notes to financial statements. 3 Table of Contents Annovis Bio, Inc. (Unaudited) Three Months Ended Six Months Ended June 30, June 30, 2025 2024 2025 2024 Operating expenses: Research and development $ 5,161,921 $ 5,785,217 $ 10,173,438 $ 12,307,308 General and administrative 1,109,532 1,977,421 2,380,696 3,265,137 Total operating expenses 6,271,453 7,762,638 12,554,134 15,572,445 Operating loss ( 6,271,453 ) ( 7,762,638 ) ( 12,554,134 ) ( 15,572,445 ) Other income (expense): Interest income 191,395 25,978 379,007 70,146 Other financing costs (Note 7) — ( 1,346,060 ) — ( 1,346,060 ) Change in fair value of warrants (Note 7) ( 140,000 ) 4,

Notes to Financial Statements

Notes to Financial Statements (Unaudited) (1) Nature of Business, Going Concern and Management's Plan Annovis Bio, Inc. (the "Company" or "Annovis") was incorporated on April 29, 2008, under the laws of the State of Delaware. Annovis is a late-stage clinical drug platform company addressing neurodegeneration, such as Alzheimer's disease ("AD") and Parkinson's disease ("PD"). The toxic cascade in neurodegeneration begins with high levels of neurotoxic proteins, which lead to impaired axonal transport, inflammation, death of nerve cells and loss of cognition and motor function. The Company's lead product candidate, buntanetap, is a small molecule administered orally that is designed to attack neurodegeneration by entering the brain and inhibiting the translation of multiple neurotoxic proteins, thereby impeding the toxic cascade. High levels of neurotoxic proteins lead to reduced axonal transport, which is responsible for the communication between and within nerve cells. When that communication is compromised, the immune system is activated and attacks the nerve cells, eventually killing them. The Company has shown in its clinical studies in AD and PD patients as well as in pre-clinical studies in mice and rats that buntanetap lowered neurotoxic protein levels, leading to improved axonal transport, reduced inflammation, lower nerve cell death and improved affected functions. Going Concern Since its founding, the Company has been engaged in organizational activities, including raising capital, as well as research and development activities. The Company has no t generated substantial revenues and has not yet achieved profitable operations, nor has it ever generated positive cash flows from operations. There is no assurance that profitable operations, if achieved, could be sustained on a continuing basis. The Company is subject to those risks associated with any clinical stage pharmaceutical company that has substantial expenditures for research and development.

View Full Filing

View this 10-Q filing on SEC EDGAR